Penn State Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania.
Center for Health Care and Policy Research, Penn State University, University Park, Pennsylvania.
Cancer. 2021 May 1;127(9):1507-1516. doi: 10.1002/cncr.33390. Epub 2020 Dec 17.
Multiple international organizations have called for exercise to become standard practice in the setting of oncology care. The feasibility of integrating exercise within systemic chemotherapy has not been investigated.
Patients slated to receive infusion therapy between April 2017 and October 2018 were screened for possible inclusion. The study goal was to establish the acceptability and feasibility of embedding an exercise professional into the chemotherapy infusion suite as a method of making exercise a standard part of cancer care. The exercise prescriptions provided to patients were individualized according to results of brief baseline functional testing.
In all, 544 patients were screened, and their respective treating oncologists deemed 83% of them to be medically eligible to participate. After further eligibility screening, 226 patients were approached. Nearly 71% of these patients (n = 160) accepted the invitation to participate in the Exercise in All Chemotherapy trial. Feasibility was established because 71%, 55%, 69%, and 63% of the aerobic, resistance, balance, and flexibility exercises prescribed to patients were completed. Qualitative data also supported the acceptability and feasibility of the intervention from the perspective of patients and clinicians. The per-patient cost of the intervention was $190.68 to $382.40.
Embedding an exercise professional into the chemotherapy infusion suite is an acceptable and feasible approach to making exercise standard practice. Moreover, the cost of the intervention is lower than the cost of other common community programs. Future studies should test whether colocating an exercise professional with infusion therapy could reach more patients in comparison with not colocating.
Few studies have tested the implementation of exercise for patients with cancer by embedding an exercise professional directly into the chemotherapy infusion suite. The Exercise in All Chemotherapy trial shows that this approach is both acceptable and feasible from the perspective of clinicians and patients.
多个国际组织呼吁将运动纳入肿瘤治疗常规。尚未研究在全身化疗中整合运动的可行性。
筛选了 2017 年 4 月至 2018 年 10 月期间接受输液治疗的患者，以评估他们是否符合入组条件。本研究的目的是确定将运动专业人员纳入化疗输液室的可接受性和可行性，从而将运动作为癌症治疗的标准部分。根据简要基线功能测试的结果，为患者制定个体化的运动处方。
共筛选了 544 名患者，他们各自的肿瘤治疗医生认为其中 83%的患者在医学上有资格参加。经过进一步的资格筛选，共 226 名患者被邀请参加“所有化疗中的运动”试验。该试验的可行性是通过以下数据建立的：71%（n=160）的患者接受了邀请参与“所有化疗中的运动”试验；71%、55%、69%和 63%的患者完成了规定的有氧运动、抗阻运动、平衡运动和柔韧性运动；从患者和临床医生的角度来看，定性数据也支持该干预措施的可接受性和可行性。该干预措施的每位患者的成本为 190.68 美元至 382.40 美元。
将运动专业人员嵌入化疗输液室是使运动成为常规实践的一种可接受且可行的方法。此外，该干预措施的成本低于其他常见社区项目的成本。未来的研究应测试将运动专业人员与输液治疗相结合是否比不结合能使更多的患者受益。
很少有研究通过将运动专业人员直接嵌入化疗输液室来测试为癌症患者实施运动的情况。“所有化疗中的运动”试验表明，从临床医生和患者的角度来看，这种方法是可以接受且可行的。
